wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884
Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
P2860
Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42360803-004FF46D-FE01-42CD-B2C6-27B0BA8B2884
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b8939e0ec52ada3ef959712a9b4e881a6e58525d
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.